GlassScriptPhysician profile
Jeffrey D Miles
NPI 1902008899
$19,187.58
in general payments reported to CMS, 2019-2025
18 companies · $6,309 in 2025
The $6,309 reported for 2025 was more than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.20 · 2020: $92.36 · 2021: $101 · 2022: $3,554 · 2023: $5,160 · 2024: $3,890 · 2025: $6,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,303 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,913.00 |
| Food and Beverage | $2,302.57 |
| Education | $142.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $11,801.98 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $5,360.73 | 2022-2025 | Ultomiris |
| Abbvie INC. | $696.19 | 2022-2025 | |
| Ucb, INC. | $455.55 | 2023-2025 | Rystiggo, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $185.44 | 2022-2024 | Austedo Xr |
| Amgen INC. | $137.09 | 2020-2025 | Uplizna |
| Pfizer INC. | $93.93 | 2023 | |
| Tanabe Pharma America, INC. | $70.07 | 2019-2023 | |
| Janssen Biotech, INC. | $65.11 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.14 | 2023-2024 | Gammagard, Hyqvia |
| Alnylam Pharmaceuticals INC. | $58.79 | 2024-2025 | Amvuttra, Onpattro |
| Allergan, INC. | $48.29 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $46.51 | 2025 | |
| Biotronik INC. | $28.42 | 2020 | |
| Biogen, INC. | $24.48 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amylyx Pharmaceuticals, INC. | $20.72 | 2023 | Relyvrio |
| Neurelis, INC. | $20.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.